Autolus Therapeutics plc
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Autolus Therapeutics plc
MorphoSys Pins Hopes On Pelabresib For Near-Term Value After Tumultuous 2022
The German biotech has highlighted its myelofibrosis drug candidate, pelabresib, as a key value driver going forward after a year of hard knocks and lackluster Monjuvi sales that forced the firm to downsize its workforce and cease preclinical operations.
Autolus Taps Markets After CAR-T Success In Pivotal Leukemia Trial
The UK firm’s obe-cel has met the primary endpoint in a Phase II acute lymphocytic leukemia trial, triggering filing plans and a $150m public offering as observers commend the drug’s competitive safety profile.
Deal Watch: Aging-Focused Calico Taps Start-Up Terray For Discovery
Terray/Calico tie-up will focus on small molecule discovery for diseases of aging, including cancer. Lilly, AstraZeneca sign discovery pacts with Nimbus and Illumina, respectively.
Deal Watch: Bristol Accesses Tech Platforms From SyntheX, Autolus
Pharma will partner with SyntheX on targeted protein degradation, with Autolus on cell therapy safety. Novo Nordisk gets rights to Ventus’s lead compound in NASH and chronic kidney disease.
- Drug Delivery
- Gene Therapy, Cell Therapy
- Other Names / Subsidiaries
- Autolus Limited
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.